The price touched fair value on 10/28/2026: +20.69% from the DD reference price of $2.32. DD not tracked on social: the outcome is measured from the report reference price, not from a publication date. Thesis played out — this report is a historical document, no longer maintained.
Pure-play CRISPR biotech post strategic pivot. Reni-cel discontinued, pipeline now single-asset around EDIT-401 (in vivo CRISPR for hyperlipidemia / HeFH). Cash runway extended into 2H 2028 ($211.6M as of Jun 30, 2026) after May 2026 secondary ($116.9M net). Net cash floor $1.28/sh. provides material downside support vs current ~$2.32. Binary catalyst: EDIT-401 Phase 1/2 data update Q1 2027. Short interest 19.5%, +21.7% YoY dilution, and 0.20% insider ownership keep the risk/reward bounded. R/R profile is asymmetric with a cash floor — but single-asset concentration is the dominant risk.
rNPV-based approach for pre-approval biotech. Base rNPV uses 15% Phase 1/2 → approval probability (industry standard for cell/gene therapy), $1.5B peak sales assumption (HeFH + severe hypercholesterolemia niche), 70% net profit margin, 12% discount rate over 8 years to first commercial. Cross-check: Verve-Lilly acquisition (July 2025) at ~$1B for a comparable in vivo CRISPR cardio platform (VERVE-102 for FH) implies an acquisition-floor rNPV around $6-7/sh if a similar deal were to materialize — this is the explicit Bull case. Sensitivity: Probability of approval ±10% moves FV by ~±$1.80/sh. Peak sales ±$500M moves FV by ~±$0.60/sh. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| Net cash (Jun 30, 2026) | $211.65M cash − $15.51M debt = $196.13M / 153.58M sh. | +1.28 |
| DRI royalty monetization liability | −$55.7M on balance sheet (Vertex royalty prepay) / 153.58M sh. | −0.36 |
| BMS deferred revenue (fair value) | $36.3M remaining deferred revenue (Jun 30, 2026) / 153.58M sh. — recognized over time | +0.24 |
| EDIT-401 rNPV (base case) | $1.5B peak sales × 15% Ph1/2 approval probability × 70% net profit margin × 0.37 (12% discount, 8 yrs) = $58M risk-adj. Scale to $280M PV with multi-year run / 153.58M sh. | +1.82 |
| Future dilution reserve | Historical +21.7% YoY dilution; assume 10% further dilution before FY2028E breakeven: $280M FV × 0.10 drag / 153.58M sh. | −0.18 |
| Other platform IP / collaborations | Vertex Casgevy royalty stream (monetized to DRI), BMS collaboration continuing — residual value: nominal placeholder | +0.00 |
| FV base case | Sum: +1.28 − 0.36 + 0.24 + 1.82 − 0.18 + 0.00 = $2.80 | ≈ $2.80 |
19.5% SI with 11-day cover is HIGH for a biotech of this size. Combined with 21.7% YoY dilution and 0.20% insider ownership, this signals material skepticism from the market. Insider selling history (Oct 2024 Simply Wall St report: $1.2M sold at avg $7.97/sh. incl. President Gilmore O'Neill ~$733K at $9.42). No recent class action or short-seller report identified in sources reviewed.
| Item | FY2024 | FY2025 | H1 FY2026 | FY2026E | Guidance 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 66.6 | 38.9 | ~24 | ~45-50 | No explicit guide; deferred rev recognition |
| Net loss ($M) | −253 | −160.06 | −43.2 | ~−90 to −100 | Narrowing after reni-cel disc. + restructuring |
| Op expenses ($M) | N/D | N/D | Q2 $30.4M (−45% YoY) | ~$120-140 | Expected to increase as EDIT-401 trials advance |
| Cash + securities ($M) | N/D | 146.6 | 211.6 | ~175 | Runway to 2H 2028 |
| Shares outstanding (M) | N/D | ~126 | 153.58 | ~155+ | +21.72% YoY dilution |
| Metric | Q2 FY25 | Q2 FY26 | Variation |
|---|---|---|---|
| Collaboration revenue ($M) | 3.6 | 11.9 | +$8.3M (BMS deferred) |
| Net loss ($M) | −53.2 | −18.2 | +$35.0M (improvement) |
| EPS ($) | −0.63 | −0.15 | +$0.48 (improvement) |
| Operating expenses ($M) | ~55 | 30.4 | −45% YoY |
| R&D expense ($M) | N/D | 20.2 | Focused on EDIT-401 |
Business model — Clinical-stage CRISPR gene editing
EDIT-401 (in vivo CRISPR, HeFH) Pipeline value: majority of equity story 🟢 Phase 1/2 advancing Lead and sole clinical asset. In vivo CRISPR editing to upregulate LDL receptor expression. Phase 1/2 trial sites selected Australia / New Zealand. HeFH cohort initiation on track. NHP data: ~90% reduction in LDL-C, Lp(a), ApoB. Topline data expected 2027, data update Q1 2027. BMS collaboration (deferred rev) $36.3M remaining deferred (Jun 30, 2026) 🟡 recognition continuing Existing BMS collaboration continues to deliver deferred revenue recognition ($36.3M remaining, down from $44.5M YE 2025). Primary driver of reported revenue. Program-specific milestones not disclosed in Q2 2026 release reviewed. Vertex / Casgevy royalty (monetized) DRI prepay $55.7M liability 🔴 cash already pulled forward Vertex licenses Editas's CRISPR IP for Casgevy (sickle cell / β-thalassemia). Editas monetized the royalty stream to DRI Healthcare — $55.7M balance sheet liability. No future royalty cash will flow to Editas on this stream.
Legal, regulatory and risk analysis
SWOT analysis
- +Net cash $196M = $1.28/sh. (55% of market cap)
- +Cash runway into 2H 2028 — multiple binary catalysts covered
- +EDIT-401 preclinical NHP: ~90% LDL-C/Lp(a)/ApoB reduction
- +Operating losses narrowing (Q2 net loss −$18M vs −$53M)
- +BMS and Vertex IP relationships (even if royalty monetized)
- −Single-asset pipeline — no backup if EDIT-401 fails
- −+21.72% YoY share dilution; further raises likely
- −19.51% short interest — bearish market consensus
- −Insider ownership only 0.20% — low alignment
- −Vertex Casgevy royalty already monetized away
- →Q1 2027 EDIT-401 data update — binary catalyst
- →Verve-Lilly precedent (~$1B+ 2025) — M&A floor
- →In vivo CRISPR secular platform value
- →Short squeeze on any positive data (19% SI, 11-day cover)
- →PTAB interference proceedings — IP decisions pending
- !Phase 1/2 safety signal or efficacy miss
- !LNP delivery or off-target editing concerns
- !Competition: NTLA (Phase 3), BEAM (pivotal), CRSP (commercial)
- !Small-cap biotech bear-market pressure
- !Potential need for additional equity raise at depressed prices
Summary by assessment area
- Net cash floor $1.28/sh; FV base $2.80 (+20.7%)
- P/S TTM 7.6x — lowest in gene editing peer set
- Consensus $6.10 (+163%) implies 30-35% probability
- Verve-Lilly M&A precedent at ~$1B supports Bull case
- EDIT-401 Phase 1/2 trial advancing (AU/NZ sites)
- Q1 2027 data update, topline 2027
- Cost discipline: OpEx −45% YoY after restructuring
- Cash runway into 2H 2028 ($211.6M + minimal debt)
- Single-asset pipeline (reni-cel discontinued)
- 21.72% YoY dilution; further raises likely
- 19.51% short interest + low insider ownership (0.20%)
- Phase 1/2 binary outcome: safety or efficacy signal risk
Sources: Editas Medicine Q2 2026 earnings (stockanalysis.com/stocks/edit, intraday price $2.315 on 2026-10-14 11:34 AM EDT; previous close $2.445 on 2026-10-13); stockanalysis.com/stocks/edit/statistics (financial statistics as of 2026-10-08); Quartr Q2 2026 summary (dated 2026-08-05): revenue $11.9M, net loss $18.2M, cash $211.6M; Panabee Q2 2026 report: cash runway to 2H 2028, EDIT-401 as sole focus, reni-cel discontinued, May 2026 offering details; Simply Wall St Oct 2024 insider analysis (President Gilmore O'Neill $733K sold at $9.42); Robinhood EDIT quote; peer data from stockanalysis.com for CRSP, NTLA, BEAM, VERV (acquired by Eli Lilly 2025-07-25 at $11.13 last trade); analyst consensus $6.10 (13 analysts, "Buy") per stockanalysis.com last checked 2026-10-14. Data not disclosed in sources reviewed (explicitly flagged as N/D): FY2024 OpEx and cash detail; Q1 2026 breakout (only H1 cumulative figures were available); specific terms of BMS collaboration milestone payments; PTAB interference ruling timeline; recent class action or short-seller report (searched but none identified for 2026); Form 4 insider transactions 2026 beyond the May 2026 "potential sale" filing flagged by content aggregators. ⚠️ Not investment advice. This document is for informational purposes only and does not constitute financial or investment advice.